Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease
Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study
Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation
Phase III Regorafenib Trial Meets PFS Primary Endpoint
Radium-233 Dichloride Increased Overall Survival in Phase III Trial
Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone
Nexavar Phase III Trial Fails To Meet Primary Endpoint
Alimta/Cisplatin Chemotherapy Increased Overall Survival
New Carfilzomib Combination Produces Near Remissions
Trial Data: No Benefit In Adding Perifosine to Capecitabine
Blinatumomab Demonstrates High Response Rate in ALL
MET Inhibitor Improved Time To Progression by 56 Percent
NCI-Approved CTEP Trials For The Month of June
Trending Stories
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Trump 2016: A look back at the 45th president’s impact on oncology
- Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Rooting out the “illegal and immoral discrimination” of DEI is the first order of business for Trump
